Have you or your loved ones been diagnosed with acute exacerbation of chronic obstructive airways disease?

You may be eligible to participate in a acute exacerbation of chronic obstructive airways disease clinical trial.

Have you or your loved ones been diagnosed with acute exacerbation of chronic obstructive airways disease? You may be eligible to participate in a acute exacerbation of chronic obstructive airways disease clinical trial.

What is a clinical trial? Is participating in a clinical trial right for you? Learn more

Acute Exacerbation of Chronic Obstructive Airways Disease Clinical Trial in Hvidovre
NCT01513655 | Phase 4 | Interventional

Have you or your loved ones been diagnosed with acute exacerbation of chronic obstructive airways disease?

You may be eligible to participate in a acute exacerbation of chronic obstructive airways disease clinical trial.

Have you or your loved ones been diagnosed with acute exacerbation of chronic obstructive airways disease? You may be eligible to participate in a acute exacerbation of chronic obstructive airways disease clinical trial.

Recruiting

Male & Female

All ages

This study is looking to recruit 150 Participants

Background: In chronic obstructive pulmonary disease, the prognosis for patients who have survived an episode of acute hypercapnic respiratory failure due to an exacerbation is poor. Despite being shown to improve survival and quality-of-life in stable patients with chronic hypercapnic respiratory failure, long-term noninvasive ventilation is controversial in unstable patients with frequent exacerbations, complicated by acute hypercapnic respiratory failure. In an uncontrolled group of patients with previous episodes of acute hypercapnic respiratory failure, treated with noninvasive ventilation, we have been able to reduce mortality and the number of repeat respiratory failure and readmissions by continuing the acute noninvasive ventilatory therapy as a long-term therapy. Methods: Multi-center open label randomized controlled trial of 150 patients having survived an admission with noninvasive ventilatory treatment of acute hypercapnic respiratory failure due chronic obstructive pulmonary disease. The included patients are randomized to usual care or to continuing the acute noninvasive ventilation as a long-term therapy, both with a one-year follow-up period. End points: The primary endpoint is one-year mortality; secondary endpoints are time to death or repeat acute hypercapnic respiratory failure, number of readmissions and repeat acute hypercapnic respiratory failure, exacerbations, dyspnea, quality of life, sleep quality, lung function, and arterial gases.